Does VEGF-targeted active immunotherapy induce complete abrogation of platelet VEGF levels?
Javier Sánchez RamírezMónica Bequet-RomeroYanelys Morera DíazFrancisco Hernández-BernalMarta Ayala AvilaPublished in: BMC research notes (2019)
Before vaccination, platelets of cancer patients carried more VEGF than the levels seen in platelet of healthy individuals. However, after vaccination, cancer patients had platelet VEGF values within the range established by healthy individuals, indicating that the antibody response elicited by CIGB-247 is not able to induce a complete suppression of VEGF. Vaccination with CIGB-247 helps to normalize VEGF levels within platelets.